On a disclosed annual basis, revenue fell from KRW 635 billion in 2022 to KRW 594.6 billion in 2023, down 6.4% year on year, then rose to KRW 653.3 billion in 2024 and KRW 722.3 billion in 2025, up 9.9% and 10.6% respectively, so revenue has grown for two consecutive years from 2024 to 2025.
Operating profit was largest in 2022 at KRW 62 billion and smallest in 2024 at KRW 33.8 billion, with 2023 at KRW 43 billion, down 30.6%, and 2025 at KRW 50.2 billion, up 48.3%. The operating margin moved from 9.8% in 2022 to 7.2% in 2023, 5.2% in 2024 and 7.0% in 2025.
In 2023, analysts pointed to customer losses and lower orders amid an economic slowdown, plus higher depreciation from hard-capsule expansion.
In 2024, the cost-of-sales ratio rose from 78.38% in 2022 to 84.20%, and the company's annual report cited higher raw material costs, weaker consumer demand from inflation and stronger global competition.
In 2025, hard-capsule profitability recovered to the low-to-mid 10% range in the second half, but a larger share of low-margin health functional foods, first-half inventory clearance and export-related costs held the full-year margin near 7%.
Profit attributable to controlling shareholders was KRW 34 billion in 2022, KRW 6.12 billion in 2023 (down 82.0%), KRW 18.3 billion in 2024 (up 198.7%) and KRW 43.5 billion in 2025 (up 138.0%), with growth in both 2024 and 2025.
Net income including non-controlling interests was KRW 47.1 billion in 2025, the gap versus controlling-shareholder profit reflecting minority interests.
Quarterly, operating profit went from KRW 13.7 billion in the third quarter of 2025 to KRW 4.82 billion in the fourth quarter, then KRW 21.2 billion in the first quarter of 2026, KRW 22.5 billion in the second quarter and KRW 11 billion in the third quarter.
Third-quarter 2026 revenue of KRW 188.4 billion was up 1.8% year on year, while operating profit was down 19.7%. Profit attributable to controlling shareholders for the last four quarters totals KRW 37 billion.
The debt-to-equity ratio was 96.1% at end-2025, with equity of KRW 541 billion and operating cash flow rising from KRW 56.2 billion in 2024 to KRW 76.9 billion in 2025.